Status:
COMPLETED
Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis
Lead Sponsor:
Keymed Biosciences Co.Ltd
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
6-11 years
Phase:
PHASE1
PHASE2
Brief Summary
This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.
Eligibility Criteria
Inclusion
- With atopic dermatis.
- Voluntarily sign the informed consent form.
Exclusion
- Any major surgery planned during the research period.
- With intestinal parasitic infection within the first 6 months of screening.
- With any previous malignant tumors prior to screening.
- With any circumstance that is not suitable to participate in this study.
Key Trial Info
Start Date :
December 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 4 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06162507
Start Date
December 22 2023
End Date
July 4 2024
Last Update
October 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Children's Hospital Capital Medical University
Beijing, China